secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001127537-25-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M
-----------------------------------------------------------------------

- Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).
- Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.
- Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.
- Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.
- Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/0001127537-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000041/lung-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001127537-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer